Can A REMS Mitigate CV Risks? Avandia, Meridia Offer Point, Counterpoint
Executive Summary
As US FDA weighs fate of Takeda’s febuxostat, advisory committee members suggest REMS to ensure prescribers have informed benefit/risk conversation with patients, but agency staff highlight design and assessment challenges for such a program.
You may also be interested in...
Takeda’s Uloric Gets CV Death Warning And Restricted Indication, But No REMS
Despite advisory committee pressure, US FDA stands firm against imposing REMS targeted at gout drug’s cardiovascular risks; however, Takeda must conduct utilization study to see if labeling changes impact prescribing patterns.
Uloric U-Turn: Gout Therapy Likely To Stay On Market Despite CV Safety Concern
US FDA would not have approved Takeda’s Uloric but for a post-market safety study commitment. Now that the study is complete and suggests a potential increased risk of mortality, however, FDA doesn’t seem inclined to pull the product.
Is There A REMS In Uloric’s Future? US FDA Panelists Say Yes, Agency Says Not Likely
Continued availability of Takeda’s febuxostat should be restricted to second-line use in gout patients who cannot tolerate or fail allopurinol, advisory committee majority says, opposing market withdrawal; but panelists’ suggestion that a Risk Evaluation and Mitigation Strategy be put in place to ensure patients and prescribers discuss cardiovascular risks receives pushback from agency.